Surgical Science Q3 2023: Weak growth, margins continued expanding - Redeye

Redeye updates its estimates following Surgical Science’s Q3 2023 report, which featured considerably lower-than-expected sales. EBITDA and EBIT margins exceeded our estimates by c3%-points. We judge growth will recover in 2024e and nudge down our valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/958434/surgical-science-q3-2023-weak-growth-margins-continued-expanding?utm_source=finwire&utm_medium=RSS